USRE32969E - Injectionable visoelastic ophthalmic gel - Google Patents

Injectionable visoelastic ophthalmic gel Download PDF

Info

Publication number
USRE32969E
USRE32969E US07/116,579 US11657987A USRE32969E US RE32969 E USRE32969 E US RE32969E US 11657987 A US11657987 A US 11657987A US RE32969 E USRE32969 E US RE32969E
Authority
US
United States
Prior art keywords
percent
weight
polymer
iaddend
iadd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime, expires
Application number
US07/116,579
Inventor
Seymour F. Trager
Victoria S. Chylinski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/625,249 external-priority patent/US4540568A/en
Application filed filed Critical
Priority to US07/116,579 priority Critical patent/USRE32969E/en
Application granted granted Critical
Publication of USRE32969E publication Critical patent/USRE32969E/en
Adjusted expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52Hydrogels or hydrocolloids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/14Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/16Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00Materials characterised by their function or physical properties
    • A61L2400/06Flowable or injectable implant compositions

Definitions

  • This invention relates to ophthalmic surgery and treatment. More particularly, this invention relates to a composition particularly suitable for use as an adjunct in ophthalmic surgery.
  • ophthalmic surgical procedures are carried out in a viscoelastic medium so as to prevent mechanical damage and denudation of the tissue surfaces.
  • Sodium hyaluronate is currently widely used as the viscoelastic substance, presenting both positive and negative facets in ophthalmic surgical procedures.
  • the hyaluronate has been reported as protecting the corneal endothelium; however, great care must be exercised in the use of hyaluronate, and in many instances, undesirable post-operative pressure increases have been noted, with dilation and, in some instance, adhesion development between the posterior capsule and the iris.
  • a further object of the present invention is to provide an improved injectionable viscoelastic solution which may be employed without postoperative complications in such anterior segment surgical procedures as cataract removal, corneal transplants, penetrating keratoplasty, correctional treatment of bullous rhegmatogenous retinal detachment and the like.
  • an improved viscoelastic gel comprising:
  • an acrylamide polymer selected from polyacrylamide and polymethacrylamide
  • the polyacrylamides found to be effective in the present compositions are polymers having a molecular weight of from about 1 to 6 million, produced by the polymerization of acrylamide, methacrylamide, or mixtures thereof by methods known to the art.
  • the polymers Preferably, have a molecular weight on the order of about 5 million. Inclusion of the polymer in the gel formulation is maintained within from about 2 to about 5 percent by weights, preferably from about 3.5 to about 4.5 percent by weight, and most preferably about 4.0 percent by weight.
  • a particularly suitable formulation is a 4.0 percent by weight polymer gel containing 0.49 percent by weight sodium chloride, 0.075 percent by weight potassium chloride, 0.048 percent by weight calcium chloride, 0.03 magnesium chloride hexahydrate and 0.17 sodium citrate dihydrate as the buffering agent.
  • sodium citrate dihydrate is preferred as a gel buffer
  • other pharmaceutically acceptable buffering agents such as sodium phosphates and sodium borates may be advantageously employed.
  • composition is formulated by autoclaving at sterilization temperatures an 8-10 percent by weight of the polymer and admixing the sterile gel with the premixed salt solution. It has been found that compounding of the polymer with the salt constituents prior to sterilization results in a rise in pH above an acceptable level.
  • the viscoelastic gels of the present invention are, as previously stated, particularly useful in ocular surgical procedures as a surgical adjunct, exhibiting:
  • the gel when utilized in standard testing for biocompatibility and irritation determinations, produced no adverse reactions in the ocular tissues of the test animals.
  • the gel when utilized in standard testing for biocompatibility and irritation determinations, produced no adverse reactions in the ocular tissues of the test animals.

Abstract

An improved injectionable viscoelastic gel for use in opthalmic surgical and treatment procedures, wherein the gelling agent is a high molecular weight polyacrylamide or polymethacrylamide.

Description

.Iadd.This is a continuation-in-part of Ser. No. 434,412, filed Oct. 14, 1982, now abandoned. .Iaddend.
BACKGROUND OF THE INVENTION
This invention relates to ophthalmic surgery and treatment. More particularly, this invention relates to a composition particularly suitable for use as an adjunct in ophthalmic surgery.
In surgical procedures involving ocular tissue such as, for example, anterior segment surgery, it is always necessary to protect the corneal endothelium from mechanical damage. Failure to provide adequate protection can result in irreparable damage to the tissue.
Presently, ophthalmic surgical procedures are carried out in a viscoelastic medium so as to prevent mechanical damage and denudation of the tissue surfaces. Sodium hyaluronate is currently widely used as the viscoelastic substance, presenting both positive and negative facets in ophthalmic surgical procedures. Positively, the hyaluronate has been reported as protecting the corneal endothelium; however, great care must be exercised in the use of hyaluronate, and in many instances, undesirable post-operative pressure increases have been noted, with dilation and, in some instance, adhesion development between the posterior capsule and the iris.
It is an object of the present invention to provide an improved injectionable ocular surgical and treatment adjunct.
It is a further object of the present invention to provide an improved injectionable viscoelastic solution which is nonreactive with ocular tissues.
A further object of the present invention is to provide an improved injectionable viscoelastic solution which may be employed without postoperative complications in such anterior segment surgical procedures as cataract removal, corneal transplants, penetrating keratoplasty, correctional treatment of bullous rhegmatogenous retinal detachment and the like.
These and other objects will become apparent from the disclosure which follows.
STATEMENT OF THE INVENTION
In accordance with the present invention, there is provided an improved viscoelastic gel comprising:
an acrylamide polymer selected from polyacrylamide and polymethacrylamide
sodium chloride
potassium chloride
calcium chloride
magnesium chloride hexahydrate
sodium acetate
buffer
water
In this particularly effective formulation, it has been found that the effectiveness thereof is achieved by compounding the constituents thereof within certain, well-defined ranges and by employing polyacrylamides and polymethacrylamides of certain, well-defined molecular weights.
The polyacrylamides found to be effective in the present compositions are polymers having a molecular weight of from about 1 to 6 million, produced by the polymerization of acrylamide, methacrylamide, or mixtures thereof by methods known to the art. Preferably, the polymers have a molecular weight on the order of about 5 million. Inclusion of the polymer in the gel formulation is maintained within from about 2 to about 5 percent by weights, preferably from about 3.5 to about 4.5 percent by weight, and most preferably about 4.0 percent by weight.
The remaining constituents of the formulation are present in the following amounts, based upon percent by weight:
______________________________________                                    
sodium chloride  0.4-8.6                                                  
potassium chloride                                                        
                 0.075-0.3                                                
calcium chloride 0.04-0.33                                                
magnesium chloride                                                        
                 0.02-0.04                                                
hexahydrate                                                               
sodium acetate   0.3-0.4                                                  
buffer           0.15-0.20                                                
water            remainder                                                
______________________________________                                    
A particularly suitable formulation is a 4.0 percent by weight polymer gel containing 0.49 percent by weight sodium chloride, 0.075 percent by weight potassium chloride, 0.048 percent by weight calcium chloride, 0.03 magnesium chloride hexahydrate and 0.17 sodium citrate dihydrate as the buffering agent.
While sodium citrate dihydrate is preferred as a gel buffer, other pharmaceutically acceptable buffering agents such as sodium phosphates and sodium borates may be advantageously employed.
The composition is formulated by autoclaving at sterilization temperatures an 8-10 percent by weight of the polymer and admixing the sterile gel with the premixed salt solution. It has been found that compounding of the polymer with the salt constituents prior to sterilization results in a rise in pH above an acceptable level.
The viscoelastic gels of the present invention are, as previously stated, particularly useful in ocular surgical procedures as a surgical adjunct, exhibiting:
(a) protective properties for corneal endothelium, iris and retinal tissue;
(b) superior properties as an aqueous humor replacement;
(c) ability to maintain a deep anterior chamber during operative procedures;
(d) ability to separate effectively tissue surfaces and thereby minimize adhesion; and
(e) biocompatibility with intra ocular tissues.
The particular effectiveness of this specific formulation as an adjunct in ophthalmic surgery is a direct result of its balanced viscoelastic properties. The viscous nature thereof provides mechanical protection for tissues (iris, retina) and cell layers (corneal endo- and epithelium) which may be exposed to mechanical damage during surgery. Further, due to the physical properties of the formulation, the gel does not flow out of the anterior chamber, providing a deep anterior chamber during surgical manipulations.
The following example serves to illustrate the present invention.
EXAMPLE 1
An autoclaved polyacrylamide having a molecular weight of about 5 million was admixed with a premixed salt solution to yield the following homogenous gel composition:
______________________________________                                    
Component        Percent by Weight                                        
______________________________________                                    
polyacrylamide   4.0                                                      
sodium chloride  0.049                                                    
potassium chloride                                                        
                 0.075                                                    
calcium chloride 0.048                                                    
magnesium chloride                                                        
                 0.030                                                    
hexahydrate                                                               
sodium acetate   0.390                                                    
sodium citrate dihydrate                                                  
                 0.170                                                    
water            remainder                                                
______________________________________                                    
The gel, when utilized in standard testing for biocompatibility and irritation determinations, produced no adverse reactions in the ocular tissues of the test animals.
EXAMPLE 2
An autoclaved polymethacrylate having a molecular weight of about 5 million was admixed with a premixed salt solution to yield the following homogenous gel composition:
______________________________________                                    
Component        Percent by Weight                                        
______________________________________                                    
polymethacrylamide                                                        
                 4.0                                                      
sodium chloride  0.049                                                    
potassium chloride                                                        
                 0.075                                                    
calcium chloride 0.048                                                    
magnesium chloride                                                        
                 0.030                                                    
hexahydrate                                                               
sodium acetate   0.390                                                    
sodium citrate dihydrate                                                  
                 0.170                                                    
water            remainder                                                
______________________________________                                    
The gel, when utilized in standard testing for biocompatibility and irritation determinations, produced no adverse reactions in the ocular tissues of the test animals.

Claims (9)

What is claimed is:
1. An injectionable viscoelastic gel particularly adapted for use in ophthalmic surgical procedures and treatments .[.which.]..Iadd., said .Iaddend.gel consisting essentially of from about 2 to about 5 percent by weight of a polymer selected from polyacrylamide and polymethacrylamide, said polymer having a molecular weight of from about 1 to about 6 million.[.;.]..Iadd., .Iaddend.from about 0.4 to about 8.6 percent by weight sodium chloride, from about 0.075 to about 0.3 percent by weight .[.postassium.]. .Iadd.potassium .Iaddend.chloride, from about 0.04 to about 0.33 percent by weight calcium chloride, from about 0.02 to about 0.04 percent by weight magnesium chloride hexahydrate, from about 0.3 to about 0.4 percent by weight sodium acetate, from about 0.15 to about 0.20 percent by weight of a buffer, remainder water.
2. A gel as defined in claim 1 wherein said polymer is polyacrylamide.
3. A gel as defined in claim 1 wherein said polymer is present in an amount of from about 3.5 to about 4.5 percent by weight.
4. A gel as defined in claim 1 wherein said polymer has a molecular weight of from about 4.5 to about 5.5 million.
5. A gel as defined in claim 1 wherein said buffer is sodium citrate dihydrate.
6. A gel as defined in claim 1 consisting essentially of about 4 percent by weight of said polymer having a molecular weight of about 5 million, about 0.049 percent by weight sodium chloride, about 0.075 percent by weight potassium chloride, about 0.048 percent by weight calcium chloride, about 0.03 percent by weight magnesium chloride hexahydrate, about 0.17 percent by weight sodium citrate dihydrate, remainder water. .Iadd.
7. A method for protecting ocular tissue during ophthalmic surgery which comprises
injecting into an ocular chamber prior to said surgery an amount of viscoelastic gel sufficient to prevent mechanical damage and denudation of said ocular tissue during said surgery, said viscoelastic gel comprising a polymer selected from polyacrylamide, polymethacrylamide and a copolymer of acrylamide and methacrylamide, said polymer having a molecular weight of from about 1 to 6 million, and a pharmaceutically acceptable diluent therefor. .Iaddend. .Iadd.8. The method of claim 7 wherein said surgical procedure is an anterior segment surgical procedure. .Iaddend. .Iadd.9. The method of claim 8 wherein said anterior segment surgical procedure is cataract removal, corneal transplant, keratoplasty or bullous
rhegmatogenous retinal detachment. .Iaddend. .Iadd.10. The method of claim 7 wherein said polymer is present in an amount between about 2 to about 5 percent by weight of said viscoelastic gel. .Iaddend. .Iadd.11. The method of claim 7 wherein said polymer is present in an amount between about 3.5 to about 4.5 percent by weight of said viscoelastic gel. .Iaddend. .Iadd.12. The method of claim 7 wherein said polymer is present in an amount between about 4.5 to about 5.5 percent by weight of said viscoelastic gel. .Iaddend. .Iadd.13. The method of claim 7 wherein said polymer is present in an amount between about 4 percent by weight of said viscoelastic gel. .Iaddend. .Iadd.14. The method of claim 7 wherein said polymer is polyacrylamide. .Iaddend. .Iadd.15. The method of claim 7 wherein said viscoelastic gel comprises
(a) 2 to 5 percent by weight of said polymer;
(b) 0.4 to 8.6 percent by weight sodium chloride;
(c) 0.075 to 0.3 percent by weight potassium chloride;
(d) 0.04 to 0.33 percent by weight calcium chloride;
(e) 0.02 to 0.04 percent by weight magnesium chloride hexahydrate;
(f) 0.3 to 0.4 percent by weight sodium acetate;
(g) 0.15 to 0.20 percent by weight buffering agent; and
(h) remainder water. .Iaddend. .Iadd.16. The method of claim 15, wherein said buffering agent is sodium citrate dihydrate. .Iaddend. .Iadd.17. The method of claim 7 wherein said viscoelastic gel consists essentially of about 4 percent by weight of said polymer having a molecular weight of about 5 million, about 0.49 percent by weight sodium chloride, about 0.075 percent by weight potassium chloride, about 0.048 percent by weight calcium, about 0.03 percent by weight magnesium chloride hexahydrate, about 0.17 percent by weight sodium citrate dihydrate, remainder water. .Iaddend.
US07/116,579 1982-10-14 1987-08-24 Injectionable visoelastic ophthalmic gel Expired - Lifetime USRE32969E (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US07/116,579 USRE32969E (en) 1982-10-14 1987-08-24 Injectionable visoelastic ophthalmic gel

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43441282A 1982-10-14 1982-10-14
US06/625,249 US4540568A (en) 1982-10-14 1984-06-27 Injectionable viscoelastic ophthalmic gel
US07/116,579 USRE32969E (en) 1982-10-14 1987-08-24 Injectionable visoelastic ophthalmic gel

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US43441282A Continuation-In-Part 1982-10-14 1982-10-14
US06/625,249 Reissue US4540568A (en) 1982-10-14 1984-06-27 Injectionable viscoelastic ophthalmic gel

Publications (1)

Publication Number Publication Date
USRE32969E true USRE32969E (en) 1989-06-27

Family

ID=27381848

Family Applications (1)

Application Number Title Priority Date Filing Date
US07/116,579 Expired - Lifetime USRE32969E (en) 1982-10-14 1987-08-24 Injectionable visoelastic ophthalmic gel

Country Status (1)

Country Link
US (1) USRE32969E (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505959A (en) * 1990-10-04 1996-04-09 Nestec S.A. Pharmaceutical composition in gel form in a dispensing package
US5629008A (en) * 1992-06-02 1997-05-13 C.R. Bard, Inc. Method and device for long-term delivery of drugs
US5631243A (en) * 1990-07-03 1997-05-20 Collagenesis Inc. Collagen-based viscoelastic solution for visco-surgery
US5639796A (en) * 1991-02-12 1997-06-17 C.R. Bard, Inc. Injectable medical composition and method of use
US5813411A (en) * 1996-08-20 1998-09-29 Menlo Care, Inc. Method of deforming tissue with a swollen hydrogel
US5855615A (en) * 1996-06-07 1999-01-05 Menlo Care, Inc. Controller expansion sphincter augmentation media
US6306418B1 (en) * 1992-08-20 2001-10-23 Robert Steven Bley Controlled expansion sphincter augmentation media
US6423332B1 (en) 2000-05-26 2002-07-23 Ethicon, Inc. Method and composition for deforming soft tissues
US20040167480A1 (en) * 2003-02-21 2004-08-26 Advanced Medical Optics, Inc. Administration of multiple viscoelastic solutions with a multi-compartment syringe
US7049346B1 (en) 1996-08-20 2006-05-23 Menlo Care Div Of Ethicon, Inc. Swollen hydrogel for sphincter augmentation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3868445A (en) * 1972-11-30 1975-02-25 Pharmacia Ab Dosage unit containing a substance showing a topical effect on the eye, and a method of preparing same
US3920810A (en) * 1974-04-23 1975-11-18 Burton Parsons And Company Inc Polyacrylamide containing ophthalmic solutions
US3978201A (en) * 1972-11-27 1976-08-31 Gennady Lvovich Khromov Base for ophthalmological medicinal preparation on opthalmological medicinal film
US4003991A (en) * 1974-08-27 1977-01-18 National Patent Development Corporation Ophthalmic formulation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3978201A (en) * 1972-11-27 1976-08-31 Gennady Lvovich Khromov Base for ophthalmological medicinal preparation on opthalmological medicinal film
US3868445A (en) * 1972-11-30 1975-02-25 Pharmacia Ab Dosage unit containing a substance showing a topical effect on the eye, and a method of preparing same
US3920810A (en) * 1974-04-23 1975-11-18 Burton Parsons And Company Inc Polyacrylamide containing ophthalmic solutions
US4003991A (en) * 1974-08-27 1977-01-18 National Patent Development Corporation Ophthalmic formulation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Chem. Abst. 76:90019(j) (1972) Lemp et al. *
Chem. Abst. 76:90019(j) (1972)-Lemp et al.
Chem. Abst., 76:90018(h) (1972) Leong et al. *
Chem. Abst., 76:90018(h) (1972)-Leong et al.

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631243A (en) * 1990-07-03 1997-05-20 Collagenesis Inc. Collagen-based viscoelastic solution for visco-surgery
US5505959A (en) * 1990-10-04 1996-04-09 Nestec S.A. Pharmaceutical composition in gel form in a dispensing package
US5639796A (en) * 1991-02-12 1997-06-17 C.R. Bard, Inc. Injectable medical composition and method of use
US5733562A (en) * 1991-02-12 1998-03-31 C.R. Bard, Inc. Injectable medical device and method of use
US5629008A (en) * 1992-06-02 1997-05-13 C.R. Bard, Inc. Method and device for long-term delivery of drugs
US6306418B1 (en) * 1992-08-20 2001-10-23 Robert Steven Bley Controlled expansion sphincter augmentation media
US6592859B1 (en) * 1992-08-20 2003-07-15 Ethicon, Inc. Controlled expansion sphincter augmentation media
US5855615A (en) * 1996-06-07 1999-01-05 Menlo Care, Inc. Controller expansion sphincter augmentation media
US5813411A (en) * 1996-08-20 1998-09-29 Menlo Care, Inc. Method of deforming tissue with a swollen hydrogel
US7049346B1 (en) 1996-08-20 2006-05-23 Menlo Care Div Of Ethicon, Inc. Swollen hydrogel for sphincter augmentation
US6423332B1 (en) 2000-05-26 2002-07-23 Ethicon, Inc. Method and composition for deforming soft tissues
US20040167480A1 (en) * 2003-02-21 2004-08-26 Advanced Medical Optics, Inc. Administration of multiple viscoelastic solutions with a multi-compartment syringe

Similar Documents

Publication Publication Date Title
US4540568A (en) Injectionable viscoelastic ophthalmic gel
US4965253A (en) Viscoelastic material for ophthalmic surgery
US4819617A (en) Viscoelastic material for ophthalmic surgery
US5518732A (en) Bio-erodible ophthalmic shield
USRE32969E (en) Injectionable visoelastic ophthalmic gel
JPH09216826A (en) Ophthalmic preparation of sodium hyaluronate-predominant medicine for ophthalmic surgery
US5492936A (en) Bimodal molecular weight hyaluronate formulations and methods for using same
EP1023077B1 (en) Opthalmic composition
AU2013347897A1 (en) Compositions and methods for reducing oxidative damage
AU621390B2 (en) Intraocular anticoagulant comprising antithrombin iii and method of administration
KR20060131938A (en) New free-radical scavenger containing viscoelastic composition, methods of use and package
JP3751017B2 (en) Bimodal molecular weight hyaluronate formulations and methods of use
Burke et al. Comparison of the effects of two viscoelastic agents, Healon and Viscoat, on postoperative intraocular pressure after penetrating keratoplasty
CN107812243A (en) A kind of corneal protection viscoelastic liquid
Alpar et al. Comparison of Healon and Viscoat in cataract extraction and intraocular lens implantation
CN108671270A (en) Viscoelastic agent material with redox characteristic
RU2513997C1 (en) Combined ophthalmic preparation presented in form of eye drops and containing polyhexamethylene guanidine and taurine
US6368585B1 (en) Opthalmic compositions and methods
JPS6281319A (en) High-viscosity preparation for medical use
JPH0236128A (en) Intraocular injection agent
WO2001051065A1 (en) Perfusion liquid preparations for ophthalmic operations
US3658963A (en) Method of reducing intraocular pressure with a basic thymol ether
EP3804773A1 (en) Viscoelastic agent material
RU2168968C2 (en) Method for setting strangulated iris from cornea and sclera wound in early postoperative period
EP0236636A2 (en) Use of clonidine derivatives for the preparation of ocular hemostatic agents

Legal Events

Date Code Title Description
PTEF Application for a patent term extension

Free format text: PRODUCT NAME: ORCOLON (POLYACRYLAMIDE); REQUESTED FOR 888 DAYS

Filing date: 19910528

Expiry date: 20020910

PTEG Grant of a patent term extension

Free format text: PRODUCT NAME: ORCOLON (POLYACRYLAMIDE)

Filing date: 19910528

Expiry date: 20020910

FEPP Fee payment procedure

Free format text: PAT HOLDER CLAIMS SMALL ENTITY STATUS - SMALL BUSINESS (ORIGINAL EVENT CODE: SM02); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
FEPP Fee payment procedure

Free format text: PETITION RELATED TO MAINTENANCE FEES DENIED/DISMISSED (ORIGINAL EVENT CODE: PMFD); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FEPP Fee payment procedure

Free format text: PETITION RELATED TO MAINTENANCE FEES GRANTED (ORIGINAL EVENT CODE: PMFG); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FEPP Fee payment procedure

Free format text: PETITION RELATED TO MAINTENANCE FEES FILED (ORIGINAL EVENT CODE: PMFP); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

SULP Surcharge for late payment